查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1471968

神經調節設備市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按類型、應用、生物材料和最終用戶

Neuromodulation Devices Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, Biomaterial, and End User
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

依據「2030 年神經調節設備市場預測 - 全球和地區佔有率、趨勢和成長機會分析 - 按類型、應用、生物材料和最終用戶」的最新研究，2022 年市場估值為 57.3 億美元，預計到2030年將達116.1億美元；預計2022年至2030年複合年成長率為9.2%。

神經調節裝置是一種可以調節神經系統活動的先進醫療儀器。此技術用於治療肌張力失調、帕金森氏症、震顫等運動障礙；耳鳴;強迫症;感覺障礙；癲癇;膀胱控制；頭痛;慢性疼痛;中風;最低意識狀態；痙攣;和脊髓損傷。

據世界衛生組織稱，2022年，美國將記錄5,000萬例癲癇病例、10億例偏頭痛病例和40萬例脊髓損傷病例。脊髓刺激是治療慢性背痛最優選的技術之一，主要是由於脊髓神經控制疼痛感的解剖學和功能能力。脊髓損傷的發生率在過去十年中有所增加。國家脊髓損傷統計中心 (NSCISC) 2021 年情況說明書指出，脊髓損傷的年發生率為每百萬人 60 例。根據2022年4月發表的題為《創傷性脊髓損傷的流行病學：一項基於大規模人群的研究》的文章，創傷性脊髓損傷的總體年齡-性別標準化發病率為每100萬人口中26.5例，發病率為與兩性的年齡有關。根據同一來源，在老年人口（≥65歲）中，男性和女性的發生率分別為每100萬中59.2人和23.3人。脊髓刺激器可用於控制與脊椎手術相關的術後疼痛。脊髓手術數量的增加推動了對脊髓刺激器的需求。因此，老年人和成年人脊髓損傷的高發生率刺激了對神經調節裝置的需求。

按應用分類，神經調節設備市場洞察

神經調節設備市場依應用分為深部腦部刺激（DBS）、薦神經刺激（SNS）、胃電刺激（GES）、脊髓刺激（SCS）和迷走神經刺激（VNS）。脊髓刺激細分市場在 2022 年佔據最大市場佔有率，預計 2022 年至 2030 年期間將創下市場最高複合年成長率。脊髓刺激已使用多年，並被建議用於越來越多的病症。此療法可幫助治療頸椎和腰椎神經根炎、背部手術失敗症候群、複雜區域疼痛症候群和神經病變。脊髓刺激在慢性疼痛治療​​中有效、安全且具有成本效益。較新的脊髓刺激技術正在擴大內臟疼痛和缺血性疼痛等臨床適應症，並有可能進一步提高療效。

透過生物材料、神經調節設備市場的見解

根據生物材料，神經調節設備市場分為金屬、聚合物和陶瓷。 2022年，金屬細分市場佔據市場佔有率。然而，聚合物細分市場可能在 2022 年至 2030 年期間實現最高的複合年成長率。在神經調節裝置中，經常使用金屬生物材料，特別是在電極和其他需要高度耐用和導電的部件中。由於其巨大的強度重量比和卓越的生物相容性，鈦及其合金經常用於神經調節裝置。

疾病管制與預防中心以及巴西神經科學和神經技術研究所是在準備神經調節設備市場報告時提到的一些主要的一手和二手來源。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解
  • 市場吸引力分析

第 3 章：研究方法

第 4 章：神經調節設備市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈供應商名單

第 5 章：神經調節設備市場 - 主要市場動態

  • 主要市場促進因素
  • 主要市場限制
  • 主要市場機會
  • 未來的趨勢
  • 促進因素和限制因素的影響分析

第 6 章：神經調節設備市場 - 全球市場分析

  • 神經調節設備 - 全球市場概覽
  • 神經調節設備 - 全球市場與 2030 年預測

第 7 章：神經調節設備市場 - 收入分析 - 按類型，2020-2030 年

  • 概述
  • 內部的
  • 外部的

第 8 章：神經調節設備市場 - 收入分析 - 按應用分類，2020-2030 年

  • 概述
  • 深部腦部刺激 (DBS)
  • 胃電刺激 (GES)
  • 脊髓刺激 (SCS)
  • 迷走神經刺激 (VNS)
  • 薦神經刺激 (SNS)

第 9 章：神經調節設備市場 - 收入分析 - 按生物材料，2020-2030 年

  • 概述
  • 金屬色
  • 聚合
  • 陶瓷製品

第 10 章：神經調節設備市場 - 收入分析 - 按最終用戶，2020-2030 年

  • 概述
  • 醫院
  • 診所
  • 家庭醫療保健

第 11 章：神經調節設備市場 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

註 - 將為以下提到的地區/國家提供類似的分析

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第13章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與專注

第 14 章：神經調節設備市場 - 主要公司簡介

  • Boston Scientific Corporation
  • Abbott
  • LivaNova PLC
  • Nevro Corp
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Synapse Biomedical Inc.
  • Aleva Neurotherapetics SA
  • Bioventus
  • EnteroMedics Inc

第 15 章：附錄

簡介目錄
Product Code: TIPRE00018069

According to our latest study on "Neuromodulation Devices Market Forecast to 2030 - Global and Regional Share, Trend, and Growth Opportunity Analysis - by Type, Application, Biomaterial, and End User," the market was valued at US$ 5.73 billion in 2022 and is expected to reach US$ 11.61 billion by 2030; it is estimated to register a CAGR of 9.2% from 2022 to 2030.

Neuromodulation devices are advanced medical instruments that can adjust the activity of the nervous system. The technology is used to treat movement disorders such as dystonia, Parkinson's disease, and tremor; tinnitus; obsessive-compulsive disorder; sensory disabilities; epilepsy; bladder control; headache; chronic pain; stroke; minimally conscious state; spasticity; and spinal cord injury.

According to the WHO, in 2022, the US recorded 50 million epilepsy cases, 1 billion migraine cases, and 400,000 spinal cord injury cases. Spinal cord stimulation is one of the most preferred techniques in treating chronic back pain, primarily due to the anatomical and functional abilities of the spinal cord nerves to control the sensation of pain. The incidence of spinal cord injuries has grown over the past decade. The National Spinal Cord Injury Statistical Center (NSCISC) 2021 fact sheet states that the annual incidence of spinal cord injuries is 60 cases per million. According to the article titled "Epidemiology of traumatic spinal cord injuries: a large population-based study," published in April 2022, the overall age-sex standardized incidence rate of traumatic spinal cord injuries was 26.5 per 1 million population, and the rates were related to age in both sexes. According to the same source, in elderly (>= 65 years) population, the rate is 59.2 and 23.3 per 1 million in males and females, respectively. Spinal cord stimulators can be useful in managing postoperative pain associated with spinal surgery. An increase in number of spinal cord surgeries propels the demand for spinal cord stimulators. Therefore, high incidence of spinal cord injuries in old age and adults stimulates the demand for neuromodulation devices.

By Application, Neuromodulation Devices Market-Based Insights

The neuromodulation devices market, by application, is segmented into deep brain stimulation (DBS), sacral nerve stimulation (SNS), gastric electrical stimulation (GES), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS). The spinal cord stimulation segment held the largest market share in 2022 and is expected to record the highest CAGR in the market during 2022-2030. Spinal cord stimulation has been used for years and is advised for a growing number of conditions. Cervical and lumbar radiculitis, failed back surgery syndrome, complex regional pain syndrome, and neuropathy are a few conditions that the therapy can assist. Spinal cord stimulation is efficacious, safe, and cost effective in chronic pain management. Newer spinal cord stimulation technologies are expanding clinical indications such as visceral and ischemic pain, with potential for further improved efficacy.

By Biomaterial, Neuromodulation Devices Market -Based Insights

Based on biomaterial, the neuromodulation devices market is segmented into metallic, polymeric, and ceramic. In 2022, the metallic segment dominated the market share. However, the polymeric segment is likely to register the highest CAGR during 2022-2030. In neuromodulation devices, metallic biomaterials are frequently utilized, especially in electrodes and other parts that need to be highly durable and electrically conductive. Owing to their great strength-to-weight ratio and exceptional biocompatibility, titanium and its alloys are frequently used in neuromodulation devices.

Center for Disease Control and Prevention, and Brazilian Institute of Neuroscience and Neurotechnology are a few of the major primary and secondary sources referred to while preparing the report on the neuromodulation devices market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Neuromodulation Devices Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Neuromodulation Devices Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Neuromodulation Devices Market - Global Market Analysis

  • 6.1 Neuromodulation Devices - Global Market Overview
  • 6.2 Neuromodulation Devices - Global Market and Forecast to 2030

7. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Internal
  • 7.3 External

8. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Deep Brain Stimulation (DBS)
  • 8.3 Gastric Electrical Stimulation (GES)
  • 8.4 Spinal Cord Stimulation (SCS)
  • 8.5 Vagus Nerve Stimulation (VNS)
  • 8.6 Sacral Nerve Stimulation (SNS)

9. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By Biomaterial, 2020-2030

  • 9.1 Overview
  • 9.2 Metallic
  • 9.3 Polymeric
  • 9.4 Ceramic

10. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Home Healthcare

11. Neuromodulation Devices Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Neuromodulation Devices Market Overview
    • 11.1.2 North America Neuromodulation Devices Market Revenue and Forecasts to 2030
    • 11.1.3 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Type
    • 11.1.4 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Application
    • 11.1.5 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Biomaterial
    • 11.1.6 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Neuromodulation Devices Market
        • 11.1.7.1.1 United States Neuromodulation Devices Market, by Type
        • 11.1.7.1.2 United States Neuromodulation Devices Market, by Application
        • 11.1.7.1.3 United States Neuromodulation Devices Market, by Biomaterial
        • 11.1.7.1.4 United States Neuromodulation Devices Market, by End User
      • 11.1.7.2 Canada Neuromodulation Devices Market
        • 11.1.7.2.1 Canada Neuromodulation Devices Market, by Type
        • 11.1.7.2.2 Canada Neuromodulation Devices Market, by Application
        • 11.1.7.2.3 Canada Neuromodulation Devices Market, by Biomaterial
        • 11.1.7.2.4 Canada Neuromodulation Devices Market, by End User
      • 11.1.7.3 Mexico Neuromodulation Devices Market
        • 11.1.7.3.1 Mexico Neuromodulation Devices Market, by Type
        • 11.1.7.3.2 Mexico Neuromodulation Devices Market, by Application
        • 11.1.7.3.3 Mexico Neuromodulation Devices Market, by Biomaterial
        • 11.1.7.3.4 Mexico Neuromodulation Devices Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Neuromodulation Devices Market - Key Company Profiles

  • 14.1 Boston Scientific Corporation
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 14.2 Abbott
  • 14.3 LivaNova PLC
  • 14.4 Nevro Corp
  • 14.5 NeuroPace, Inc.
  • 14.6 NeuroSigma, Inc.
  • 14.7 Synapse Biomedical Inc.
  • 14.8 Aleva Neurotherapetics SA
  • 14.9 Bioventus
  • 14.10 EnteroMedics Inc

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud